Risk factors of severe cases with COVID-19: a meta-analysis

被引:100
作者
Ou, Mingchun [1 ]
Zhu, Jieyun [2 ]
Ji, Pan [2 ]
Li, Hongyuan [2 ]
Zhong, Zhimei [2 ]
Li, Bocheng [2 ]
Pang, Jielong [2 ]
Zhang, Jianfeng [2 ]
Zheng, Xiaowen [2 ]
机构
[1] Peoples Hosp Baise, Dept Pharm, Baise 533000, Peoples R China
[2] Guangxi Med Univ, Dept Emergency, Affiliated Hosp 2, Nanning 530007, Peoples R China
关键词
Coronavirus disease 2019; critically ill; meta-analysis; risk factors; severe disease; CORONAVIRUS DISEASE 2019; CLINICAL CHARACTERISTICS; WUHAN; THROMBOCYTOPENIA;
D O I
10.1017/S095026882000179X
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Our study aimed to systematically analyse the risk factors of coronavirus disease 2019 (COVID-19) patients with severe disease. An electronic search in eight databases to identify studies describing severe or critically ill COVID-19 patients from 1 January 2020 to 3 April 2020. In the end, we meta-analysed 40 studies involving 5872 COVID-19 patients. The average age was higher in severe COVID-19 patients (weighted mean difference; WMD = 10.69, 95%CI 7.83-13.54). Patients with severe disease showed significantly lower platelet count (WMD = -18.63, 95%CI -30.86 to -6.40) and lymphocyte count (WMD = -0.35, 95%CI -0.41 to -0.30) but higher C-reactive protein (CRP; WMD = 42.7, 95%CI 31.12-54.28), lactate dehydrogenase (LDH; WMD = 137.4, 95%CI 105.5-169.3), white blood cell count(WBC), procalcitonin(PCT?, D-dimer, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatinine(Cr?. Similarly, patients who died showed significantly higher WBC, D-dimer, ALT, AST and Cr but similar platelet count and LDH as patients who survived. These results indicate that older age, low platelet count, lymphopenia, elevated levels of LDH, ALT, AST, PCT, Cr and D-dimer are associated with severity of COVID-19 and thus could be used as early identification or even prediction of disease progression.
引用
收藏
页数:11
相关论文
共 54 条
[1]  
[Anonymous], 2020, J 3 MILITARY MED U, DOI DOI 10.16016/J.1000-5404.202002097
[2]  
[Anonymous], 2020, SHANGHAI MED J
[3]  
[Anonymous], COR DIS 2019 COVID 2
[4]  
Chen M, 2020, HER MED, V41, P1, DOI DOI 10.3870/j.issn.1004-0781.2020.04.007
[5]  
Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
[6]  
Chen W, 2020, J INNER MONGOLIA MED, V42
[7]  
Chen X, 2020, INT J CLIN EXP MED, V13, P2002
[8]  
Deng YT, 2020, CAMB CHINA LIBR, P1
[9]  
Fang XW, 2020, CHINESE PHARMACOL B
[10]  
Gao W, 2020, ACAD J CHINESE PLA M